Wei Di
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wei Di has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Xiaolei Shi
Cerebrovascular Disease Department, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, China
2 shared publications - Aneta Wieczorek
Department of Prosthodontics and Orthodontics, Institute of Dentistry, Faculty of Medicine, Jagiellonian University Medical College, 31-155 Krakow, Poland
1 shared publication Bin Tang
The Second Affiliated Hospital of GuangZhou Medical University
1 shared publication- Hong Zhang
Department of Neurology, Shaanxi Provincial People’s Hospital, The Third Affiliated Hospital of Xi’an Jiaotong University, Shaanxi, 710068, China
1 shared publication - Hua Lv
Department of Neurology Shaanxi Provincial People's Hospital Xi'an China
1 shared publication - Hua Lv
Department of Neurology, Shaanxi Provincial People’s Hospital, The Third Affiliated Hospital of Xi’an Jiaotong University, Shaanxi, 710068, China
1 shared publication
Latest Publications
- Open Access
- 12 March 2020
- Published by Hindawi Limited in Pain Research and Management
- Vol. 2020, 1-2
Basic and Clinical Advances in the Diagnosis and Management of Migraine
- 12 March 2020
- Published by Hindawi Limited in Pain Research and Management
- Vol. 2020, 1-2
Open AccessBasic and Clinical Advances in the Diagnosis and Management of Migraine
- 14 November 2018
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 139 (3) , 284-293
Efficacy of CoQ10 as supplementation for migraine: A meta-analysis
Objectives Migraine ranks among the most frequent neurological disorders globally. Co‐enzyme Q10 (CoQ10) is a nutritional agent that might play a preventative role in migraine. This meta‐analysis aimed to investigate the effects of CoQ10 as a supplemental agent in migraine. Subjects and methods Web of Science, PubMed and Cochrane Library were searched for potential articles that assessed the effects of CoQ10 on migraine. Data were extracted by two independent reviewers and analyzed with Revman 5.2 software. Results We included 5 studies with 346 patients (120 pediatric and 226 adult subjects) in the meta‐analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P P = 0.009). Conclusion This is the first study to demonstrate the effects of CoQ10 supplementation on migraine. The results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days per month. Nonetheless, more studies are needed to support the conclusions.
- 14 November 2018
- Published by Wiley in Acta Neurologica Scandinavica
- Vol. 139 (3) , 284-293
Efficacy of CoQ10 as supplementation for migraine: A meta-analysis
Objectives Migraine ranks among the most frequent neurological disorders globally. Co‐enzyme Q10 (CoQ10) is a nutritional agent that might play a preventative role in migraine. This meta‐analysis aimed to investigate the effects of CoQ10 as a supplemental agent in migraine. Subjects and methods Web of Science, PubMed and Cochrane Library were searched for potential articles that assessed the effects of CoQ10 on migraine. Data were extracted by two independent reviewers and analyzed with Revman 5.2 software. Results We included 5 studies with 346 patients (120 pediatric and 226 adult subjects) in the meta‐analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P P = 0.009). Conclusion This is the first study to demonstrate the effects of CoQ10 supplementation on migraine. The results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days per month. Nonetheless, more studies are needed to support the conclusions.
- Open Access
- 10 July 2018
- Published by Wiley in Parkinson's Disease
- Vol. 2018, 1-7
The Association betweenLRRK2G2385R and Phenotype of Parkinson’s Disease in Asian Population: A Meta-Analysis of Comparative Studies
Numerous studies have investigated the relationship between theLRRK2G2385R variant and clinical characteristics in Parkinson’s disease (PD), but the results have been inconsistent. This study investigated whether theLRRK2G2385R variant was associated with a unique clinical phenotype of PD in the Asian population, using a meta-analysis. The PubMed, Web of Science, EMBASE, CNKI, and WANFANG databases were searched until September 2017. The strict selection criteria and exclusion criteria were determined, and mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of associations. Statistical analyses and graphics were performed using Review Manager 5.3. Sixteen related case-control studies were included in the meta-analysis. TheLRRK2G2385R carriers significantly more often presented a family history (OR: 1.98; 95% CI: 1.16−3.39;) and had a longer disease duration (MD = 0.47, 95% CI: 0.01−0.93,) and a higher MMSE score (MD = 1.02, 95% CI: 0.43–1.62) thanLRRK2G2385R noncarriers. There were no significant differences in sex distribution, age at onset, initial symptoms, motor symptoms, depression, levodopa-equivalent dose, and related complications betweenLRRK2G2385R-carrier andLRRK2G2385R-noncarrier PD patients. Our results suggested that most of the clinical characteristics of PD patients withLRRK2G2385R mutations are similar to those ofLRRK2G2385R noncarriers among Asian PD patients, except for the more common family history, relatively longer disease duration, and higher MMSE scores in the former group.- 10 July 2018
- Published by Wiley in Parkinson's Disease
- Vol. 2018, 1-7
Open AccessThe Association betweenLRRK2G2385R and Phenotype of Parkinson’s Disease in Asian Population: A Meta-Analysis of Comparative Studies
Numerous studies have investigated the relationship between theLRRK2G2385R variant and clinical characteristics in Parkinson’s disease (PD), but the results have been inconsistent. This study investigated whether theLRRK2G2385R variant was associated with a unique clinical phenotype of PD in the Asian population, using a meta-analysis. The PubMed, Web of Science, EMBASE, CNKI, and WANFANG databases were searched until September 2017. The strict selection criteria and exclusion criteria were determined, and mean differences (MD) or odds ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of associations. Statistical analyses and graphics were performed using Review Manager 5.3. Sixteen related case-control studies were included in the meta-analysis. TheLRRK2G2385R carriers significantly more often presented a family history (OR: 1.98; 95% CI: 1.16−3.39;) and had a longer disease duration (MD = 0.47, 95% CI: 0.01−0.93,) and a higher MMSE score (MD = 1.02, 95% CI: 0.43–1.62) thanLRRK2G2385R noncarriers. There were no significant differences in sex distribution, age at onset, initial symptoms, motor symptoms, depression, levodopa-equivalent dose, and related complications betweenLRRK2G2385R-carrier andLRRK2G2385R-noncarrier PD patients. Our results suggested that most of the clinical characteristics of PD patients withLRRK2G2385R mutations are similar to those ofLRRK2G2385R noncarriers among Asian PD patients, except for the more common family history, relatively longer disease duration, and higher MMSE scores in the former group. - Open Access
- 24 October 2016
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 17 (1) , 1-9
Activation of the nuclear factor E2-related factor 2/anitioxidant response element alleviates the nitroglycerin-induced hyperalgesia in rats
Antioxidants have been proven to weaken hyperalgesia in neuropathic pain. Endogenous antioxidant defense system may have a role in the prevention of hyperalgesia in migraine. In this study, we aimed to evaluate the role of nuclear factor E2-related factor 2/antioxidant response element (Nrf2/ARE) pathway in regulating the activation of the trigeminovascular system (TGVS) and hypersensitivity in nitroglycerin (NTG)-induced hyperalgesia rats. The expression levels of Nrf2, HO, HO1, and NQO1 in the trigeminal nucleus caudalis (TNC) were detected by western blot. Immunofluorescence was used to demonstrate the cell-specific localization of Nrf2 in TNC. Sulforaphane, a Nrf2 activator, was administered to NTG-induced rats. Then, the number of c-Fos- and nNOS-immunoreactive neurons in TNC was evaluated using immunofluorescence, and c-Fos and nNOS protein levels were quantified using western blot. Von Frey hair testing was used to evaluate the tactile thresholds of rats at different time points in different groups. Total cellular and nuclear levels of the proteins Nrf2, HO1, and NQO1 were elevated in TNC after NTG injection, and Nrf2 was found to be located in the nucleus and cytoplasm of the neurons. Sulforaphane pretreatment significantly increased the nuclear Nrf2, HO1, and NQO1 levels in TNC. In addition, sulforaphane exposure effectively inhibited the expression of nNOS and c-Fos, reduced the number of nNOS and c-Fos immunoreactive neurons in TNC, and attenuated the tactile thresholds induced by NTG injection. Oxidative stress was involved in nitroglycerin-induced hyperalgesia. Activation of the Nrf2/ARE pathway inhibited the activation of TGVS and prevented the induction of hyperalgesia. Sulforaphane might therefore be an effective agent for hyperalgesia. Further studies are needed to discover the underlying mechanisms of the process.
- 24 October 2016
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 17 (1) , 1-9
Open AccessActivation of the nuclear factor E2-related factor 2/anitioxidant response element alleviates the nitroglycerin-induced hyperalgesia in rats
Antioxidants have been proven to weaken hyperalgesia in neuropathic pain. Endogenous antioxidant defense system may have a role in the prevention of hyperalgesia in migraine. In this study, we aimed to evaluate the role of nuclear factor E2-related factor 2/antioxidant response element (Nrf2/ARE) pathway in regulating the activation of the trigeminovascular system (TGVS) and hypersensitivity in nitroglycerin (NTG)-induced hyperalgesia rats. The expression levels of Nrf2, HO, HO1, and NQO1 in the trigeminal nucleus caudalis (TNC) were detected by western blot. Immunofluorescence was used to demonstrate the cell-specific localization of Nrf2 in TNC. Sulforaphane, a Nrf2 activator, was administered to NTG-induced rats. Then, the number of c-Fos- and nNOS-immunoreactive neurons in TNC was evaluated using immunofluorescence, and c-Fos and nNOS protein levels were quantified using western blot. Von Frey hair testing was used to evaluate the tactile thresholds of rats at different time points in different groups. Total cellular and nuclear levels of the proteins Nrf2, HO1, and NQO1 were elevated in TNC after NTG injection, and Nrf2 was found to be located in the nucleus and cytoplasm of the neurons. Sulforaphane pretreatment significantly increased the nuclear Nrf2, HO1, and NQO1 levels in TNC. In addition, sulforaphane exposure effectively inhibited the expression of nNOS and c-Fos, reduced the number of nNOS and c-Fos immunoreactive neurons in TNC, and attenuated the tactile thresholds induced by NTG injection. Oxidative stress was involved in nitroglycerin-induced hyperalgesia. Activation of the Nrf2/ARE pathway inhibited the activation of TGVS and prevented the induction of hyperalgesia. Sulforaphane might therefore be an effective agent for hyperalgesia. Further studies are needed to discover the underlying mechanisms of the process.
- 7 September 2010
- Published by Springer Nature in neurogenetics
- Vol. 12 (1) , 93-95
A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis
- 7 September 2010
- Published by Springer Nature in neurogenetics
- Vol. 12 (1) , 93-95
A novel CLN2/TPP1 mutation in a Chinese patient with late infantile neuronal ceroid lipofuscinosis